Biostock interviews Chordate Medical CEO Anders Weilandt about Chordate’s participation at the prominent pain congress Deutsche Schmerzkongress in Mannheim, and why Germany is an important market for the company.
“The market introduction in Germany is going according to plan, and it is now a matter of getting a small number of clinics that want to get started. At the same time, we are working on various solutions so that the patient will eventually be able to receive insurance compensation for the treatment. The German market for headache is the best developed in Europe, by far. Generally, a migraine patient has very good access to structured care and specialists”, says Anders Weilandt.